CTLA4 and cancer: Bromo‐ and Extra‐Terminal (BET) protein inhibitor, which suppresses TNF‐α secretion by M1‐type macrophage, cancer cell proliferation, and VEGF‐A secretion, improves antitumor response when combined with anti‐CTLA‐4 treatment